Post-IPO Debt - Kala Pharmaceuticals - 2021-05-12 - Crunchbase

May 13, 2021 · Kala Pharmaceuticals raised $125000000 on 2021-05-12 in Post-IPO Debt. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. …

CouponFollow Extension

$125000000
OFF

Post-IPO Debt - Kala Pharmaceuticals - 2021-05-12 - Crunchbase

1 week from now

May 13, 2021 · Kala Pharmaceuticals raised $125000000 on 2021-05-12 in Post-IPO Debt. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. …

crunchbase.com

$115
OFF

Kala Pharmaceuticals - Raised $115M Funding From 16 Investors

1 week from now

Nov 5, 2024 · Kala Pharmaceuticals has raised a total funding of $115M over 11 rounds from 16 investors. Investors include Athyrium Capital Management, Vivo Capital and 14 others. ... Kala …

tracxn.com

750%
OFF

KALA BIO, Inc. (KALA) Stock Price, Quote & News - Stock Analysis

1 week from now

4 days ago · Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment. Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for …

stockanalysis.com

$20
OFF

Does Kala Pharmaceuticals (NASDAQ:KALA) Have A Healthy …

1 week from now

Jul 22, 2021 · We can see from the most recent balance sheet that Kala Pharmaceuticals had liabilities of US$20.0m falling due within a year, and liabilities of US$100.0m due beyond that. …

yahoo.com

$16122541
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2021-11-29 - Crunchbase

1 week from now

Kala Pharmaceuticals raised $16122541 on 2021-11-29 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

crunchbase.com

$31000000
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2022-11-28 - Crunchbase

1 week from now

Kala Pharmaceuticals raised $31000000 on 2022-11-28 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

crunchbase.com

$200
OFF

Staying Patient With Kala Pharmaceuticals - Seeking Alpha

1 week from now

Aug 29, 2021 · Kala Pharmaceuticals currently has a market capitalization of approximately $200 million and trades for around $3.25 a share. Pipeline: Source: August Company Presentation. …

seekingalpha.com

$31
OFF

Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2022 ...

1 week from now

Mar 3, 2023 · -- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement …

yahoo.com

$86
OFF

Kala Pharmaceuticals Files For $86 Million IPO - Seeking Alpha

1 week from now

Jun 27, 2017 · Quick Take. Eye biopharmaceutical company Kala Pharmaceuticals(NASDAQ:KALA) has filed to sell up to $86.25 million in common stock in an …

seekingalpha.com

$3
OFF

Kala Pharmaceuticals Reports Second Quarter 2021 Financial …

1 week from now

Aug 5, 2021 · Second Quarter 2021 Financial Results. Net Product Revenues: For the quarter ended June 30, 2021, Kala reported net product revenues of $3.1 million, consisting of $1.7 …

yahoo.com

$7.50
OFF

Kala Pharmaceuticals Stock Price - Markets Insider

1 week from now

Jun 25, 2024 · On Monday 11/11/2024 the closing price of the Kala Pharmaceuticals Inc Registered Shs share was $7.50 on BTT. Compared to the opening price on Monday …

businessinsider.com

FAQs about Post-IPO Debt - Kala Pharmaceuticals - 2021-05-12 - Crunchbase Coupon?

How will Kala fund its operations in 2022?

Kala anticipates that its cash resources as of December 31, 2020, together with anticipated INVELTYS revenue and the $18.2 millionin net proceeds raised in January 2021under the Company’s ATM offering program, will enable it to fund its operations into at least the fourth quarter of 2022. ...

How much did Kala pharmaceuticals (Kala) lose?

Kala Pharmaceuticals (KALA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -58.14%. ...

Does Kala bio offer non-statutory stock options?

ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside ... ...

Did Kala give a new employee non-statutory stock options?

ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement aw... ...

Will Kala's net revenues be negatively impacted in 2021?

Kala expects that net revenues could continue to be negatively impacted in 2021. Preclinical Development Program Pipeline: Kala is progressing a pipeline of preclinical development programs targeted to address front and back of the eye diseases. ...